A new kind of CRISPR that destroys cells rather than gene editing them has shown potential for killing sick cells while leaving healthy cells untouched. The technology has largely been tested in cells ...

Science and medicine are incredibly amazing. Thanks to modern science and medicine, we now have lifespans far beyond our Dark Age predecessors, living until ripe old age and enjoying the fruits of our ...

CRISPR functions as a programmable genetic memory system derived from bacterial immune defenses against viral infections. Guide RNA allows for rapid multiplexed targeting compared to older ...

CRISPR Therapeutics now has an approved gene therapy treatment in Casgevy. The treatment for sickle cell disease received regulatory approval earlier this month. Despite this positive news, the stock ...

With the first medical therapy approved and systems like CRISPR-Cas showing up in complex cells, there’s a lot happening in the genome editing field. By Amber Dance/Knowable Magazine Published Jan 26, ...

CRISPR Therapeutics (NASDAQ: CRSP) has reached a very exciting point in its story. The biotech company that specializes in gene editing is awaiting regulatory decisions on what could become its first ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...

Thanks for the cure, CRISPR. Now companies want a pill to treat sickle-cell disease instead. The company that just got approval to sell the first gene-editing treatment in history, for sickle-cell ...

Finding a quality mid-cap stock to invest in can lead to huge returns for investors down the road. These are the types of companies that are still in their early growth stages and that can possess ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...